Novartis (NOVN) Given a CHF 92 Price Target by Morgan Stanley Analysts

Novartis (VTX:NOVN) has been given a CHF 92 price target by analysts at Morgan Stanley in a report issued on Friday. The firm presently has a “buy” rating on the stock. Morgan Stanley’s price target would indicate a potential upside of 9.59% from the stock’s previous close.

A number of other equities analysts have also recently issued reports on NOVN. set a CHF 90 price objective on shares of Novartis and gave the company a “buy” rating in a research note on Tuesday, September 19th. Baader Bank set a CHF 90 target price on shares of Novartis and gave the stock a “buy” rating in a report on Monday, October 30th. Berenberg Bank set a CHF 88 target price on shares of Novartis and gave the company a “neutral” rating in a research report on Monday, October 30th. Sanford C. Bernstein set a CHF 97 target price on shares of Novartis and gave the company a “buy” rating in a research report on Thursday, October 26th. Finally, Societe Generale set a CHF 95 target price on shares of Novartis and gave the company a “buy” rating in a research report on Wednesday, October 25th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and seven have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of CHF 86.37.

Novartis (NOVN) opened at CHF 83.95 on Friday. Novartis has a 12-month low of CHF 67.80 and a 12-month high of CHF 85.40.

ILLEGAL ACTIVITY WARNING: This report was originally reported by Community Financial News and is the property of of Community Financial News. If you are viewing this report on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this report can be viewed at https://www.com-unik.info/2017/12/01/novartis-novn-given-a-chf-92-price-target-by-morgan-stanley-analysts.html.

Novartis Company Profile

Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.

Analyst Recommendations for Novartis (VTX:NOVN)

What are top analysts saying about Novartis AG? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Novartis AG and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit